Certara (NASDAQ:CERT) Shares Up 5.9% – Here’s Why

Certara, Inc. (NASDAQ:CERT) shares shot up 5.9% on Thursday . The stock traded as high as $8.89 and last traded at $8.85. 760,632 shares traded hands during trading, a decline of 79% from the average session volume of 3,699,057 shares. The stock had previously closed at $8.36.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Robert W. Baird decreased their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets cut their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings raised Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Stephens decreased their target price on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, Morgan Stanley decreased their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.28.

Certara Trading Down 3.4%

The stock has a market cap of $1.29 billion, a P/E ratio of -18.73 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The stock’s fifty day moving average is $7.11 and its 200 day moving average is $6.46.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The company had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same period in the previous year, the firm earned $0.07 earnings per share. The company’s revenue was down 10.8% compared to the same quarter last year. As a group, equities research analysts predict that Certara, Inc. will post 0.22 earnings per share for the current fiscal year.

Institutional Trading of Certara

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Harvest Management LLC bought a new stake in Certara in the second quarter worth $131,000. Jefferies Financial Group Inc. bought a new position in Certara during the second quarter valued at $46,446,000. Corient Private Wealth LP bought a new position in Certara during the second quarter valued at $346,000. Bank of America Corp DE bought a new position in Certara during the second quarter valued at $11,780,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Certara in the second quarter valued at $373,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.